Hengrui Medicine: Subsidiary Injection SHR-1826 is included in the list of breakthrough therapeutic varieties.

Notice from Hengrui Medicine: The injectable SHR-1826 of its subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., has been included in the list of breakthrough therapeutic drugs by the National Medical Products Administration Drug Evaluation Center. Injectable SHR-1826 is a c-Met targeted antibody-drug conjugate that specifically binds to target antigens on the surface of tumor cells, causing them to be internalized and killed.